You are here

Takeda

Takeda Taps Twist Bioscience to Boost Biologics Discovery Capabilities

Takeda Taps Twist Bioscience to Boost Biologics Discovery Capabilities

BioSpace

Twist Bioscience

Flag link:

Takeda’s post-merger deals continue as OTC subsidiary is prepared for sale

Takeda’s post-merger deals continue as OTC subsidiary is prepared for sale

Endpoints

Flag link:

Takeda and Carmine Enter $900 Million Non-Viral Gene Therapy Collaboration

Takeda and Carmine Enter $900 Million Non-Viral Gene Therapy Collaboration

BioSpace

Carmine Therapeutics

Flag link:

Takeda takes a $200M hit after Novartis is forced to yank its marketing application for Xiidra

Takeda takes a $200M hit after Novartis is forced to yank its marketing application for Xiidra

Endpoints

dry eye disease

Flag link:

Takeda joins microbiome-focused biotech partner's $52.6M raise as it pursues more in-house cancer work

Takeda joins microbiome-focused biotech partner's $52.6M raise as it pursues more in-house cancer work

Endpoints

Flag link:

FDA warns Takeda over aseptic processing, inadequate investigations

FDA warns Takeda over aseptic processing, inadequate investigations

RAPS.org

drug manufacturing

Flag link:

Takeda Grants License To Neurocrine Biosciences For Seven Pipeline Programs

Takeda Grants License To Neurocrine Biosciences For Seven Pipeline Programs

NASDAQ

Neurocrine Biosciences

treatment-resistant depression

Flag link:

Takeda-partnered Shattuck nabs mighty $118M funding round for immunotherapy, autoimmune work

Takeda-partnered Shattuck nabs mighty $118M funding round for immunotherapy, autoimmune work

Fierce Biotech

drug development

Flag link:

Takeda continues post-Shire selloff, inching closer to $10B goal

Takeda continues post-Shire selloff, inching closer to $10B goal

Endpoints

Flag link:

Shiny new startup Egle grabs a deal with Takeda for cancer research

Shiny new startup Egle grabs a deal with Takeda for cancer research

Fierce Biotech

Egle Therapeutics

Flag link:

Once a gem, now just a rock, Takeda punts PhIII IBD drug as rivals muscle ahead

Once a gem, now just a rock, Takeda punts PhIII IBD drug as rivals muscle ahead

Endpoints

Flag link:

Takeda posts surprise profit a year after Shire mega-merger

Takeda posts surprise profit a year after Shire mega-merger

Pharmaforum

Flag link:

Roche’s test of novel gut target nears

Roche’s test of novel gut target nears

EP Vantage

ulcerative colitis

Flag link:

Ovid's lead drug shows promising efficacy signal in Fragile X syndrome study, but optimal dosing regimen is unclear for path forward

Ovid's lead drug shows promising efficacy signal in Fragile X syndrome study, but optimal dosing regimen is unclear for path forward

Endpoints

Ovid Therapeutics

Fragile X syndrome

clinical trials

Flag link:

Takeda gets FDA breakthrough therapy status for mobocertinib to treat certain type of lung cancer

Takeda gets FDA breakthrough therapy status for mobocertinib to treat certain type of lung cancer

Pharmaceutical Business Review

metastatic non-small cell lung cancer

Flag link:

Takeda licenses ProThera plasma drug for use in inflammatory conditions

Takeda licenses ProThera plasma drug for use in inflammatory conditions

Fierce Biotech

ProThera Biologics

inflammatory diseases

plasma-based pharmaceuticals

Flag link:

Takeda to sell European OTC business to cut debts

Takeda to sell European OTC business to cut debts

Pharmaforum

Flag link:

Takeda, CSL forge coronavirus alliance, forgoing their own drugs in the process

Takeda, CSL forge coronavirus alliance, forgoing their own drugs in the process

BioPharma Dive

drug development

Flag link:

Biopharma acquisitions slow, but it's not Covid-19's fault yet

Biopharma acquisitions slow, but it's not Covid-19's fault yet

EP Vantage

Gilead Sciences

ANI Pharmaceuticals

Amerigen Pharma

Flag link:

Takeda and Evotec Enter into Gene Therapy Research Alliance

Takeda and Evotec Enter into Gene Therapy Research Alliance

BioSpace

Flag link:

Pages